Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy.

Autor: Desta Z; Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA., Gammal RS; Department of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences University School of Pharmacy, Boston, Massachusetts, USA.; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA., Gong L; Department of Biomedical Data Science, Stanford University, Stanford, California, USA., Whirl-Carrillo M; Department of Biomedical Data Science, Stanford University, Stanford, California, USA., Gaur AH; Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA., Sukasem C; Division of Pharmacogenomics and Personalized Medicine, Faculty of Medicine Ramathibodi Hospital, Department of Pathology, Mahidol University, Bangkok, Thailand.; Laboratory for Pharmacogenomics, Faculty of Medicine Ramathibodi Hospital, Somdech Phra Debaratana Medical Center, Bangkok, Thailand., Hockings J; Department of Pharmacy and Genomic Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA., Myers A; Department of Diagnostic & Biomedical Sciences, The University of Texas Health Sciences Center School of Dentistry, Houston, Texas, USA., Swart M; Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA., Tyndale RF; Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada., Masimirembwa C; African Institute of Biomedical Science & Technology, Wilkins Hospital, Harare, Zimbabwe., Iwuchukwu OF; Division of Pharmaceutical Sciences, Fairleigh Dickinson University School of Pharmacy, Florham Park, New Jersey, USA., Chirwa S; Department of Internal Medicine, Meharry Medical College School of Medicine, Nashville, Tennessee, USA., Lennox J; Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA., Gaedigk A; Division of Clinical Pharmacology, Toxicology, & Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, Missouri, USA., Klein TE; Department of Biomedical Data Science, Stanford University, Stanford, California, USA., Haas DW; Department of Internal Medicine, Meharry Medical College School of Medicine, Nashville, Tennessee, USA.; Departments of Medicine, Pharmacology, Pathology, Microbiology, & Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Jazyk: angličtina
Zdroj: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2019 Oct; Vol. 106 (4), pp. 726-733. Date of Electronic Publication: 2019 Jul 05.
DOI: 10.1002/cpt.1477
Abstrakt: The HIV type-1 nonnucleoside reverse transcriptase inhibitor, efavirenz, is widely used to treat HIV type-1 infection. Efavirenz is predominantly metabolized into inactive metabolites by cytochrome P450 (CYP)2B6, and patients with certain CYP2B6 genetic variants may be at increased risk for adverse effects, particularly central nervous system toxicity and treatment discontinuation. We summarize the evidence from the literature and provide therapeutic recommendations for efavirenz prescribing based on CYP2B6 genotypes.
(© 2019 The Authors Clinical Pharmacology & Therapeutics  © 2019 American Society for Clinical Pharmacology and Therapeutics.)
Databáze: MEDLINE
Externí odkaz: